Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
9 stopped studies mapped to Thymus Carcinoma and descendants · 100% state a reason
Over the 9 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT07181720 | CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors | Phase 1 | suspended | Sep 18, 2025 | Chongqing Precision Biotech Co., Ltd | Sponsor stopped the study. | Other (stated, no rule matched) |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor… | — | withdrawn | Aug 2, 2021 | Travera Inc | Abandoned prior to launch. | Other (stated, no rule matched) |
| NCT04925947 | A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors | Phase 2 | terminated | Jun 14, 2021 | Weill Medical College of Cornell University | Data collected did not support the study endpoints | Other (stated, no rule matched) |
| NCT04469725 | KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in… | Phase 2 | terminated | Jul 14, 2020 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | The termination of this study does not involve safety issues. The overall safety of KN046 is good,… | Safety / toxicity |
| NCT01143545 | Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and… | Phase 1 | terminated | Jun 14, 2010 | National Cancer Institute (NCI) | Closed accrual due to unpromising results and the opening of study 14C0053 targeting the same… | Enrollment / accrual |
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer… | Phase 2 | terminated | Feb 14, 2014 | Mayo Clinic | Poor accrual | Enrollment / accrual |
| NCT01011439 | Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma | Phase 2 | terminated | Nov 11, 2009 | Tiziana Life Sciences LTD | For the 2 last patients still on treated nominal therapeutic use of the Milciclib was approved at… | Other (stated, no rule matched) |
| NCT01100944 | A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and… | Phase 1 / Phase 2 | terminated | Apr 9, 2010 | National Cancer Institute (NCI) | Principal investigator left the National Institutes of Health (NIH). | Investigator |
| NCT00818090 | Paclitaxel and Cisplatin for Thymic Neoplasm | Phase 2 | terminated | Jan 7, 2009 | Korean Cancer Study Group | marginal statistical significance | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 18 days agoSource updated Sep 11, 2026source: clinicaltrials